BioSkryb Genomics, a leader in single-cell and ultra–low-input multiomic technologies, has announced the launch of its ResolveSEQ LongRead Early Access Program, in collaboration with Eremid® Genomic Services, a high-complexity genomics contract research organization (CRO) and Certified Service Provider (CSP) for BioSkryb. This exclusive program opens the door for researchers to explore a new era of single-cell whole-genome sequencing, combining the resolution and sensitivity of long-read technology with unprecedented genomic coverage from a single cell.
The Early Access Program will provide select researchers the opportunity to access and validate BioSkryb’s ResolveSEQ LongRead solution, which delivers 75–92% genomic coverage across different sample types — a dramatic improvement over previously published methods for single-cell long-read sequencing. This leap in coverage and sensitivity could transform fields such as oncology, neurology, and cell and gene therapy, where detailed insights into genomic heterogeneity and complex structural variants are critical.
Revolutionizing Single-Cell Long-Read Sequencing
ResolveSEQ LongRead represents a major advancement in single-cell sequencing technology. It integrates BioSkryb’s proprietary Primary Template-directed Amplification (PTA) with Eremid’s custom PacBio long-read library preparation, resulting in more uniform amplification and broader genomic coverage than previously possible. This tuned version of PTA achieves greater than 70% sensitivity in detecting single-nucleotide variants (SNVs) and structural changes within a single cell — offering unparalleled resolution and accuracy in genomic discovery.
In traditional single-cell long-read sequencing, researchers often faced a tradeoff between read length and genome coverage, leading to incomplete or biased genomic views. ResolveSEQ LongRead overcomes these limitations by maintaining both the long-read power to map complex genomic regions and the completeness of whole-genome coverage, creating a best-of-both-worlds solution.
“With our new ResolveSEQ LongRead solution, participants in the early access program will be able to assess complex structural rearrangements, measure lengths of gene expansions or tandem repeats, and phase SNVs in the same single cell,” said Charles Gawad, MD, PhD, Chief Scientific Officer and Co-Founder of BioSkryb Genomics. “These applications were previously inaccessible using existing single-cell long-read methods. We’re thrilled to empower researchers to uncover new biological insights across oncology, neurology, and cell and gene therapy.”
Empowering Discovery Through Collaboration
Eremid Genomic Services, a CLIA-certified, CAP-accredited genomics CRO, brings deep expertise in next-generation sequencing (NGS) and precision medicine research to the partnership. As one of BioSkryb’s Certified Service Providers, Eremid will provide early access customers with industry-leading sequencing quality, backed by years of operational excellence and data integrity.
“This partnership with BioSkryb represents more than just adding another service,” said Julien Curaba, CSO of Eremid Genomic Services. “We’ve built our reputation on delivering the highest quality genomics data, and BioSkryb’s PTA represents a major advance in next-generation single-cell genomics—offering the unprecedented accuracy and uniformity our clients demand. Through our certified laboratory, we can now provide researchers with access to world-class single-cell technology that drives meaningful discoveries in human health and precision medicine.”
By pairing Eremid’s long-read sequencing infrastructure with BioSkryb’s PTA-based amplification, researchers can expect greater confidence in variant detection, improved reproducibility, and minimized amplification bias, which are crucial for clinical and translational research applications.
Setting a New Standard in Genomic Precision
ResolveSEQ LongRead is purpose-built to address the challenges that have long limited single-cell sequencing accuracy, particularly in regions of the genome that are structurally complex or prone to sequencing errors. Traditional short-read sequencing methods often fail to detect large structural rearrangements, repeat expansions, or copy number variations (CNVs) — genomic features increasingly recognized for their roles in cancer, neurodegenerative disease, and genetic disorders.
ResolveSEQ LongRead enables researchers to:
- Resolve complex structural rearrangements — including translocations, inversions, and CNVs — within individual cells.
- Detect on- and off-target genome edits and other structural changes from gene-editing events in a single assay.
- Assess somatic mosaicism across structural variants, including repeat-rich genomic regions.
- Reveal heterogeneity within tumor samples by linking structural alterations with phased SNVs from the same cell.
This level of granularity allows for comprehensive variant interpretation and improved understanding of disease mechanisms, making it especially valuable for researchers investigating tumor evolution, neurogenomic diversity, and therapeutic resistance.
A New Era for Single-Cell Long-Read Applications
BioSkryb’s ResolveSEQ LongRead platform fills a critical gap in the genomics landscape. By combining long-read sequencing’s ability to resolve large structural variants with the high genomic coverage and sensitivity of PTA, it enables scientists to examine genomic complexity with unprecedented clarity.
For example:
- In oncology, researchers can now observe the full architecture of cancer genomes at single-cell resolution — revealing how mutations, structural rearrangements, and copy number changes contribute to tumor progression and therapeutic response.
- In neurology, the platform allows the detection of repeat expansions and somatic mosaicism, offering insights into conditions such as Huntington’s disease and ALS.
- In cell and gene therapy, it provides a powerful tool to monitor off-target effects of CRISPR and other gene-editing technologies, ensuring higher safety and precision in therapeutic development.
“With the ResolveSEQ LongRead solution, we’re giving researchers the tools they need to map the complete genomic landscape of a single cell,” said Gawad. “This not only helps decode genetic diversity within complex tissues but also drives new opportunities for translational applications that will ultimately benefit patients.”
Technology Powered by Precision and Innovation
At the core of ResolveSEQ LongRead is Primary Template-directed Amplification (PTA), a proprietary amplification chemistry developed by BioSkryb. PTA offers high uniformity, low bias, and exceptional genome representation compared to traditional multiple displacement amplification (MDA) or PCR-based approaches. When combined with long-read sequencing platforms such as PacBio HiFi sequencing, the resulting data provides both breadth and depth of insight at single-cell resolution.
The collaboration with Eremid Genomic Services ensures that this powerful combination is supported by state-of-the-art laboratory practices, certified quality management, and scalable data generation pipelines — essential for clinical research and large cohort studies.
Accelerating Precision Medicine Through Early Access
The Early Access Program for ResolveSEQ LongRead is now open to a select group of researchers and institutions, giving them the opportunity to evaluate the technology ahead of full commercial release. Participants will work directly with BioSkryb and Eremid to generate and analyze data, providing feedback that will guide the product’s refinement and broader rollout.
This program not only enables early adopters to access a transformative tool but also fosters a collaborative ecosystem of innovation where leading scientists contribute to shaping the next generation of single-cell sequencing technologies.
